Cumberland Q2 Loss Widens to $0.20/Share After Apotex Sale
CPIX has more than doubled off its 52-week low of $1.85.
Summary
Cumberland's first quarter after the $100M Apotex sale shows a $0.20 adjusted loss per share, driven by reclassification of the branded business as discontinued operations and ongoing pipeline investment. Revenue from continuing operations declined, reflecting the strategic pivot to drug development. The company remains well-capitalized after the special $1.50 dividend and $5M buyback authorization. With one analyst at hold, the market will watch for clinical milestones from the late-stage pipeline to gauge the new strategy's viability.
At the time of this announcement, CPIX was trading at $7.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.4M. The 52-week trading range was $1.85 to $8.09. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.